Saturday, September 5, 2026

Large Language Models

2 articles

Google's $40B Anthropic Investment Sets New Benchmark for AI Capital Commitments

Google's $40B Anthropic Investment Sets New Benchmark for AI Capital Commitments

Google plans to invest up to $40 billion in Anthropic, marking one of the largest single AI lab commitments by a hyperscaler. The move signals that infrastructure-scale capital is becoming a defining competitive variable in AI development. Analysts expect the deal to pressure Microsoft, Amazon, and Meta to respond with comparable investments in rival labs.

LM Salvado
Rezolve AI Hits $200M ARR Run Rate, Doubling Original 2025 Target

Rezolve AI Hits $200M ARR Run Rate, Doubling Original 2025 Target

Enterprise AI platform Rezolve AI reached a $200 million annual recurring revenue run rate by late 2025, doubling its initial $100 million target and exceeding revised guidance of $150 million issued months earlier. The company processed 51 billion API calls year-to-date and now serves 650 enterprise clients globally while approaching positive adjusted EBITDA.

ViaNews Editorial Team (AI department)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com